Essential roles for both the 23-0-mycinosyl and 4"-0-acyl moieties of4"-0-acyltylosin derivatives in the expression of antimicrobial activity against multiple macrolide-resistant strains of Staphylococci and mycoplasmas were demonstrated by in vitro comparison of the MICs oferythromycin, josamycin, tylosin and its 3-and 4"-O-acyl derivatives, demycinosyltylosin (DMT) and its 3-and 4"-0-acyl derivatives and 23-modified 3-O-acetyl-4"-0-isovaleryl-DMT derivatives.
In previous papers1~3), we reported that a variety of tylosin derivatives, which were prepared using chemical and biological methods, were screened for antimicrobial activities against multiple macrolide-resistant clinical isolates of Staphylococci and mycoplasmas. This led to the recent discovery of 4"-0-(4-methoxyphenyl)acetyltylosin (IMC-XV) which is not only active in vitro against multiple macrolide-resistant strains of Staphylococci and mycoplasmas, but also effective in vivo in treatment of experimental animal infections caused by such macrolide-resistant microbes4~6). Macrolide-resistant Staphylococci were classified into three major types depending on their inhibition pattern with different macrolide antibiotics according to Mitsuhashi et al. (type A: all macrolide compounds; type B: erythromycin and oleandomycin; type C: erythromycin)7). Structurally, josamycin and tylosin belong to the 16-membered basic macrolide group, and differ in the mycinose moiety, the 4"-0-acyl side chain and several substituents on the 16-membered aglycone ( Fig. 1 ). It would be interesting to elucidate the reason why 4"-0-acyltylosin derivatives are active against macrolide-resistant microbes, whereas josamycin is inactive.
In the meantime, a blocked mutant (YO-9010) of Streptomyces fradiae was obtained during strain improvement work, which produced demycinosyltylosin (DMT)8)9) useful for chemical synthesis of
23-modified tylosin derivatives.
This paper describes the chemical preparation and antimicrobial profiles of 23-modified 3-0-acetyl-4"-0-isovaleryl-DMT derivatives, and the results indicate synergistic roles for the mycinosyl and 4"-0-acyl moieties of 4"-0-acyltylosin derivatives in the expression of antimicrobial activities against multiple macrolide-resistant strains of Staphylococci and mycoplasmas. 
Results and Discussion
Preparation of 23-Modified N-l Derivatives After S.fradiae blocked mutant YO-9010 was found to produce a large amount ofDMTin fermentation broth9), chemical modifications were carried out to develop clinically useful derivatives from DMT.The available information on the structure-activity relationships of tylosin derivatives showedthat introduction of the 4"-0-acyl group (e.g. 3-0-acetyl-4"-0-isovaleryltylosin, AIV) was apparently useful for increased antimicrobial activity against macrolide-resistant microbes10). Thus 3-0-acetyl-4"-0-isovaleryl-DMT (N-1)1 X) which was employed as the starting macrolide compound for the chemical modifications presented here was prepared from DMTvia microbial 3,4"-di-0-acylation1).
N-l has three substituent hydroxyl groups, at C-23, C-2' and C-3". Of these groups, the 2'-OH is readily protectable as the acetyl derivative (2'-0-acetyl-N-l, 5) , and the 3"-OH needs no protection under the reaction conditions used for the 23-modifications described in this paper.
23-0-Ether derivatives (6 and 7) were prepared from 5 by treatment with neat alkyl halides in the presence of Ag2Oas acid scavenger. Whenan aprotic polar solvent such as DMFwas used, acetic acid was eliminated from the C-2 and C-3 positions.
23-Deoxy-23-oxo-N-l (8) was synthesized from 5 with DMSO-dicyclohexylcarbodiimide (DCQpyridinium trifluoroacetate. As it was rather unstable on silica gel, 8 was partially purified to about 70% by gel filtration with Sephadex LH-20. and 23-deoxy-23-dimethylamino-N-l (ll) were obtained using the methods of Tanaka et al.12) . The chemical structures of these derivatives and related macrolide compoundswere confirmed using :H NMRspectral analysis.
Antimicrobial Characterization of 23-Modified N-l Derivatives Tables 1 and 2 summarize the antibacterial and antimycoplasmal spectra of23-modified N-l derivatives and related reference macrolide compounds, respectively.
The antibacterial spectra of the new 23-modified N-l derivatives listed in Table 1 show no substantial differences in antibiotic activity from those of the reference tylosin and DMTderivatives (N-l, DMT,AIV and tylosin), indicating that except for macrolide-resistant strains the mycinose moiety is not involved in the expression of activities against these representative Gram-positive and Gram-negative bacteria. Like Table 1 . Antibacterial spectra of the 23-modified N-l derivatives and reference macrolide compounds (MIC in wg/ml). >100 >100 >100 >100 25 >100 100 50 6.25 100 100 100 12.5 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 > 100 > 100 > 100 > 100 > 100 100 >100 >100 >100 >100 >100 >100 >100 >100 > 100 > 100 50 > 100 50 25 >100 >100 >100 >100 >100 >100 >100 >100 >100 >100 25 50 12.5 12.5 >100 >100 >100 >100 > 100 > 100 100 > 100 > 100 100 100 100 25 > 100 > 100 100 100 100 25
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Comparative antimycoplasmal profiles of the new N-l derivatives, N-l , DMT,AIV, tylosin, josamycin and erythromycin (Table 2) suggested that activity against macrolide-sensitive mycoplasma strains was not influenced by the absence of the mycinose moiety, as was the case in bacteria. Even tylosin itself (without the 4"-0-acyl group) was highly active against macrolide-resistant mycoplasmas, whereas DMT was inactive, suggesting an important role for the mycinose moiety in the expression of antibiotic activity against macrolide-resistant mycoplasmas. Amongthe N-l derivatives tested, N-l was the most active, being comparableto tylosin against the resistant mycoplasmas.
Structure-activity Relationships of Tylosin and DMTDerivatives Structural comparison (Fig. 1) has revealed that tylosin differs from josamycin in substituents at C-3 (hydroxy in tylosin vs. acetoxy in josamycin), C-4 (methyl vs. methoxy), C-9 (ketone vs. hydroxy), C-12 (methyl vs. hydrogen), C-14 (mycinosyloxymethyl vs. hydrogen), C-15 (ethyl vs. methyl) and C-4" (hydroxy vs. isovaleryloxy)6>13).
For closer comparison of antimicrobial activities with josamycin, the 3-O-acetyl and 4"-0-isovaleryl series of tylosin and DMTwere selected. Table 3 compares the in vitro antibacterial activities of such tylosin and DMTderivatives (tylosin, 3-O-acetyltylosin (1), 4"-O-isovaleryltylosin (2) and AIV; DMT, 3-O-acetyl-DMT (3), 4"-0-isovaleryl-DMT (4) and N-l ), josamycin and erythromycin against macrolide-sensitive and -resistant Gram-positive bacteria. As is described above for the 23-modified N-l derivatives, the removal of mycinose from the tylosin derivatives led to no loss of antibacterial activities against macrolide-sensitive microbes, and rather the decrease in molecular weight seemed to result in slightly improved MICs. In contrast, antibacterial activities against type A macrolide-resistant microbes were drastically reduced by the loss of the mycinose moiety. Although the relative significance of the mycinosyl and 4"-0-acyl moieties in antimicrobial activity against the resistant microbes is not known, it is probable that the coexistence of the mycinose moiety and the 4"-0-isovaleryl side chain contributes to at least an 8-fold increase in antibiotic activity compared to the derivatives containing no mycinose.
Comparative antimycoplasmal activities of the tylosin and DMT derivatives, josamycin and erythromycin are shown in Table 4 . The DMT derivatives were again as active as the tylosin derivatives against the macrolide-sensitive mycoplasmas. Because of the absence of mycinose, DMTand 3 were practically inactive against the macrolide-resistant mycoplasmas. The potentiation effect of the mycinose moiety is estimated to be more than 10 times. It is interesting to note that the introduction of the 4"-O-isovaleryl side chain resulted in about a 20-fold improvement in MICagainst the macrolide-resistant mycoplasmas. This improvement was more pronounced than the improvement against the macrolideresistant bacteria due to the introduction of the 4"-0-isovaleryl side chain.
In conclusion, the existence of the mycinose moiety seems essential for antimicrobial activities against macrolide-resistant clinical isolates. This should be kept in mind when derivation of tylosin and related compound is attempted.
Experiment al
General Methodology UVabsorption spectra were determined with a Hitachi 200-20 spectrophotometer; optical rotations
were measured with a Jasco DIP-181 digital polarimeter and field desorption mass spectra (FD-MS) with a Hitachi RMU-7M mass spectrometer. XHNMR spectra were recorded on a Varian EM-390spectrometer at 90 MHzusing TMSas the internal standard. Silica gel used for column chromatography was Wakogel C-200 (Wako Pure Chemical Industries, Ltd.). Silica gel TLCwas carried out on pre-coated Silica gel 60 F254 plates (E. Merck, Darmstadt).
Antibiotic Susceptibility
The data for antibacterial and antimycoplasmal activity are given as MICs in fig/m\ . Antibacterial activity was determined using the agar dilution method with Mueller-Hinton agar (Difco Labs.) at 35°C for 18 hours with an inoculum size of about 106 cfu/ml. Antimycoplasmal activity was measured using the microtiter procedure in medium containing 1.73 g of PPLO broth (Eiken Chemical Co., Ltd.), 20ml fresh horse serum, 105u potassium benzylpenicillin and 2mg phenol red per 100ml water (pH7.8 before autoclaving). Serial 2-fold dilutions of an antibiotic in the mediumwere inoculated with an inoculum size of about 106cfu/ml of a test mycoplasma and then incubated at 35°C for 5 days. AverageMICswere calculated as arithmetic means, under the assumption that < is equal to =.
N-l N-l was prepared via microbial conversion from DMTor mycaminosyl tylonolide. The method from DMTwas similar to that described for the preparation ofAIV from tylosin1}. The method from mycaminosyl tylonolide was as follows.
Growth and fermentation media consisted of glucose 20g, soybean meal 20g, yeast extract 1 g, K2HPO40.5 g and MgSO4à"7H2O 0.5 g in 1 liter water and were adjusted to pH7.0. One loopful of mature spores of strain 8254 (a mutant strain of Streptomyces thermotolerans ATCC1 1416) on ISP-2 medium was inoculated into a 500-ml Erlenmeyer flask containing 100ml of the growth medium and cultured at 37°C for 2 days on a rotary shaker at 220rpm. The seed culture (500ml) was transferred into 100 liters of the fermentation medium in a 200-liter fermentation tank, and cultured aerobically for 24 hours at 37°C and 400rpm (aeration rate: 0.5v/v/m). Mycaminosyl tylonolide12) (20g) dissolved in 1 liter sterile water was added to the culture broth, and wasincubated for a further 24 hours under the sameconditions.
The bioconversion product was isolated using an established procedure for basic macrolides. The fermentation broth (100 liters) was filtered at pH 4.0, and the filtrate was concentrated to ca. 20 liters with a reverse osmosis concentrator. The concentrate was adjusted to pH 7.0, and extracted twice with 5 liters each of toluene. The extracts were combined and concentrated to 1 liter under reduced pressure. The toluene solution was back-extracted with 10 liters of 0.1 mcitrate buffer (pH 3.7). The aqueous extract was adjusted to pH 7.0, and extracted again with 1 liter of toluene. The toluene extract was dried over Na2SO4 and evaporated to dryness, leaving ca. 10g of a pale yellow powder. The powder was purified with silica gel column chromatography using a solvent system of benzene-acetone-methanol (30 : 10 : 1) as eluent. Eluate fractions which showed a single spot of Rf 0.28 on silica gel TLC(benzene-acetone, 2: 1) were combined and evaporated to give 1.5g of N-l as an amorphous white powder. MP115~118°C; [a]£5 -37.2°(c 0.5, MeOH); UV Aá"t°H nm (e) FD-MS m/z 868 (M+H)+.
3 was prepared via microbial conversion from DMTusing a method similar to that described for the preparation of 3-O-acetyltylosin (1)1'14) 4"-0-Isovaleryl-DMT
4 was prepared via microbial conversion from DMT9) using a method similar to that described for the preparation of 4"-0-isovaleryltylosin (2) 2'-0-Acetyl-Nl (5) NOV. 1989 Acetic anhydride (1.1 ml) was added dropwise to a solution ofN-l (5 g) in 50ml acetone. The mixture was stirred at roomtemperature for 2 hours. The reaction mixture was poured into ice-water and stirred for 30 minutes. The solution was adjusted to pH 8.0, and then extracted with toluene. The toluene solution was washed with satd sodium bicarbonate and brine, and dried over Na2SO4. After filtration, the toluene was evaporated off. The residual solid 5 (5 g) was used in the next reaction step without further purification. 
A solution in 4ml methyl iodide containing 5 (0.15g) and 80mg of Ag2O was heated under reflux for 6 hours. After cooling, the reaction mixture was filtered, and the filtrate was evaporated to dryness. The residue was subjected to purification using silica gel column chromatography (benzene -acetone, 8 : 1 as eluent) to give 46mg of 23-0-methyl-2'-(9-acetyl-N-l.
This material was dissolved in 10ml methanol, and the solution was refluxed for 7 hours. After the removal of the solvent, the residue was subjected to silica gel column chromatography (benzene-acetone 
A solution in 5ml benzyl bromide containing 5 (0.36g) and 0.15g ofAg2O was heated at 45°C for 6.5 hours. The reaction mixture was treated in a manner similar to the preparation of 23-0-methyl-N-l (6), giving 33mg of 23-O-benzyl-N-l (7). Rf 0.56 (silica gel TLC; benzene-acetone, 2: 1); UV Xá"l°H nm Pyridine (0.1ml), 0.012ml ofTFA and 277mg of DCCwere added to 200mg of5 in a mixture of 2ml DMSO and 1 ml benzene. The reaction mixture was stirred at room temperature for 3 hours and then diluted in 20ml toluene. The toluene solution was washed three times with 20ml each of water and once with 20ml of satd sodium chloride, and dried over Na2SO4. After filtration, the toluene solution was concentrated to ca. 2ml and the concentrate was subjected to Sephadex LH-20 gel filtration column chromatography (MeOH as eluent), giving 175 mg 23-deoxy-23-oxo-2'-0-acetyl-N-l. The compound was dissolved in 10 ml methanol and refluxed for 7 hours. After cooling, the methanol solution was concentrated to ca. 2ml and the concentrate was subjected to Sephadex LH-20 gel filtration column chromatography (MeOHas eluent). Fractions containing 23-deoxy-23-oxo-N-l (8) were combined and concentrated. The solvent was exchanged for ethyl acetate. The concentrated ethyl acetate solution was added dropwise into hexane to give 60 mg of23-deoxy-23-oxo-N-l 23-Deoxy-23-bromo-Nl (9)
